KRAS testing in metastatic colorectal carcinoma: Challenges, controversies, breakthroughs and beyond

Journal of Clinical Pathology

Volumn 67, Issue 1, 2014, Pages 1-9

  Malapelle, Umberto ^a   Carlomagno, Chiara ^a   De Luca, Caterina ^a   Bellevicine, Claudio ^a   Troncone, Giancarlo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895060068     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201835     Document Type: Review

References (134)

1. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74.
2. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
3. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefi t from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
4. Van Cutsem E, Kohne CH, Lang I, et al . Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011 -19.
5. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Effi cacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011;22:1535-46.
6. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705.
7. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706-13.
8. Ciardiello F, Tejpar S, Normanno N, et al. Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. Target Oncol 2011;6:133-45.
9. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-6.
10. van Krieken JH, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008;453:417-31.
11. College of American Pathologists. POET Report: perspectives on emerging technology: KRAS testing for colorectal cancer. Published September 2009. http://www.cap.org/apps/docs/committees/technology/KRAS.pdf (accessed 20 May 2013).
12. Cejas P, Lopez-Gomez M, Aguayo C, et al. Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: implications for cancer therapy. Curr Cancer Drug Targets 2012;12:124-31.
13. Oudejans JJ, Slebos RJ, Zoetmulder FA, et al. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer 1991;49:875-9.
14. Al-Mulla F, Going JJ, Sowden ET, et al. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol 1998;185:130-8. (Pubitemid 28270924)
15. Albanese I, Scibetta AG, Migliavacca M, et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun 2004;325:784-91. (Pubitemid 39487940)
16. Artale S, Sartore-Bianchi A, Veronese SM, et al . Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008;26:4217-19.
17. Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790-9.
18. Cejas P, Lopez-Gomez M, Aguayo C, et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS ONE 2009;4:e8199.
19. Garm Spindler KL, Pallisgaard N, Rasmussen AA, et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 2009;20:879-84.
20. Italiano A, Hostein I, Soubeyran I, et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 2010;17:1429 -34.
21. Lamy A, Blanchard F, Le Pessot F, et al. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Mod Pathol 2011;24:1090-100.
22. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009;101:715- 21.
23. Modest DP, Stintzing S, Laubender RP, et al. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anticancer Drugs 2011;22:913-18.
24. Molinari F, Martin V, Saletti P, et al. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer 2009;100:1087-94.
25. Oliveira C, Westra JL, Arango D, et al. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 2004;13:2303-11. (Pubitemid 39359927)
26. Perrone F, Lampis A, Orsenigo M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009;20:84-90.
27. Santini D, Loupakis F, Vincenzi B, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 2008;13:1270-5.
28. Etienne-Grimaldi MC, Formento JL, Francoual M, et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 2008;14:4830-5.
29. Losi L, Benhattar J, Costa J. Stability of K-ras mutations throughout the natural history of human colorectal cancer. Eur J Cancer 1992;28A:1115-20.
30. Miglio U, Mezzapelle R, Paganotti A, et al. Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay. Pathol Res Pract 2013;209:233-6.
31. Suchy B, Zietz C, Rabes HM. K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis. Int J Cancer 1992;52:30-3.
32. Weber JC, Meyer N, Pencreach E, et al. Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identifi ed different subtypes. Int J Cancer 2007;120:524-32. (Pubitemid 44969022)
33. Zauber P, Sabbath-Solitare M, Marotta SP, et al. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. Mol Pathol 2003;56:137-40. (Pubitemid 36724225)
34. Han CB, Li F, Ma JT, et al. Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest 2012;30:741-7.
35. Knijn N, Mekenkamp LJ, Klomp M, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011;104:1020-6.
36. Kim MJ, Lee HS, Kim JH, et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer 2012;12:347.
37. Yang QH, Schmidt J, Soucy G, et al. KRAS mutational status of endoscopic biopsies matches resection specimens. J Clin Pathol 2012;65:604-7.
38. Krol LC, t Hart NA, Methorst N, et al. Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma. Eur J Cancer 2012;48:1108- 15.
39. Fadhil W, Ibrahem S, Seth R, et al. The utility of diagnostic biopsy specimens for predictive molecular testing in colorectal cancer. Histopathology 2012;61:1117-24.
40. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science 2013;339:1546-58.
41. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
42. Ondrejka SL, Schaeffer DF, Jakubowski MA, et al. Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing?. Am J Surg Pathol 2011;35:1327-30.
43. Boissiere-Michot F, Lopez-Crapez E, Frugier H, et al. KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment. Mod Pathol 2012;25:731-9.
44. Troncone G, Malapelle U, Cozzolino I, et al. KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer. Diagn Cytopathol 2010;38:869-73.
45. Pang NK, Nga ME, Chin SY, et al. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma. Cytopathology 2011;22:358-64.
46. Bozzetti C, Negri FV, Azzoni C, et al. Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples. Diagn Cytopathol 2013;41:595-8.
47. Dogan S, Becker JC, Rekhtman N, et al. Use of touch imprint cytology as a simple method to enrich tumor cells for molecular analysis. Cancer Cytopathol 2013;121:354-60.
48. Petras ML, Lefferts JA, Ward BP, et al. KRAS detection in colonic tumors by DNA extraction from FTA paper: the molecular touch-prep. Diagn Mol Pathol 2011;20:189-93.
49. Malapelle U, Bellevicine C, Russo A, et al. KRAS testing on colo-rectal carcinoma cytological imprints. Diagn Cytopathol 2011;39:274-7.
50. Normanno N, Pinto C, Castiglione F, et al. KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. PLoS ONE 2011;6:e29146.
51. Ross JS. Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective. Arch Pathol Lab Med 2012;136:1298-307.
52. Bellon E, Ligtenberg MJ, Tejpar S, et al. External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist 2011;16:467-78.
53. Kotoula V, Charalambous E, Biesmans B, et al. KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS ONE 2009;4: e7746.
54. Morikawa T, Shima K, Kuchiba A, et al. No evidence for interference of h&e staining in DNA testing: usefulness of DNA extraction from H&E-stained archival tissue sections. Am J Clin Pathol 2012;138:122-9.
55. Weichert W, Schewe C, Lehmann A, et al. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn 2010;12:35-42.
56. Kamel-Reid S, Zhang T, Persons DL, et al. Molecular Oncology Resource Committee of the College of American P. Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma. Arch Pathol Lab Med 2012;136:26-32.
57. Neumann J, Zeindl-Eberhart E, Kirchner T, et al. requency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 2009;205:858-62.
58. Gao J, Li YY, Sun PN, et al. Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation. World J Gastroenterol 2010;16:4858-64.
59. Franklin WA, Haney J, Sugita M, et al. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn 2010;12:43-50.
60. Tol J, Dijkstra JR, Vink-Borger ME, et al. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med 2010;14:2122-31.
61. Malapelle U, Bellevicine C, Salatiello M, et al. Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective. J Clin Pathol 2012;65:940-4.
62. Hancer VS, Buyukdogan M, Turkmen I, et al. Comparison of KRAS mutation tests in colorectal cancer patients. Genet Test Mol Biomarkers 2011;15:831-4.
63. Carotenuto P, Roma C, Rachiglio AM, et al. Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics 2010;11:1169-79.
64. Tsiatis AC, Norris-Kirby A, Rich RG, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn 2010;12:425-32.
65. Soh J, Okumura N, Lockwood WW, et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS ONE 2009;4:e7464.
66. Hartman DJ, Davison JM, Foxwell TJ, et al. Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival. Int J Cancer 2012;131:1810-17.
67. Borras E, Jurado I, Hernan I, et al. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer 2011;11:406.
68. Krypuy M, Newnham GM, Thomas DM, et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 2006;6:295.
69. Ma ES, Wong CL, Law FB, et al. Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis. J Clin Pathol 2009;62:886-91.
70. Reed GH, Kent JO, Wittwer CT. High-resolution DNA melting analysis for simple and efficient molecular diagnostics. Pharmacogenomics 2007;8:597-608. (Pubitemid 46939585)
71. Simi L, Pratesi N, Vignoli M, et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 2008;130:247-53.
72. Deschoolmeester V, Boeckx C, Baay M, et al. KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. Br J Cancer 2010;103:1627-36.
73. Do H, Krypuy M, Mitchell PL, et al. Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008;8:142.
74. Kristensen LS, Daugaard IL, Christensen M, et al. Increased sensitivity of KRAS mutation detection by high-resolution melting analysis of COLD-PCR products. Hum Mutat 2010;31:1366-73.
75. Malapelle U, Carlomagno C, Salatiello M, et al. KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. Br J Cancer 2012;107:626-31.
76. Angulo B, Garcia-Garcia E, Martinez R, et al. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn 2010;12:292-9.
77. Sundstrom M, Edlund K, Lindell M, et al. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer 2010;10:660.
78. Whitehall V, Tran K, Umapathy A, et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 2009;11:543-52.
79. Dono M, Massucco C, Chiara S, et al. Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer. Mol Med 2012;18:1519-26.
80. Pinto P, Rocha P, Veiga I, et al. Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer. Cancer Genet 2011;204:439-46.
81. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72.
82. Bando H, Yoshino T, Tsuchihara K, et al. KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab. Br J Cancer 2011;105:403-6.
83. Harbison CT, Horak CE, Ledeine JM, et al. Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial. Arch Pathol Lab Med 2013;137:820-7.
84. Lee S, Brophy VH, Cao J, et al. Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma. Virchows Arch 2012;460:141-9.
85. Gonzalez de Castro D, Angulo B, Gomez B, et al. A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. Br J Cancer 2012;107:345-51.
86. Brink M, de Goeij AF, Weijenberg MP, et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 2003;24:703-10. (Pubitemid 36592405)
87. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304:1812-20.
88. Harle A, Busser B, Rouyer M, et al. TaqMan PCR and High Resolution Melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas. Virchows Arch 2013;462:329-35.
89. Ausch C, Buxhofer-Ausch V, Oberkanins C, et al. Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. J Mol Diagn 2009;11:508-13.
90. Cavallini A, Valentini AM, Lippolis C, et al. KRAS genotyping as biomarker in colorectal cancer: a comparison of three commercial kits on histologic material. Anticancer Res 2010;30:5251-6.
91. De Miglio MR, Mura A, Uras MG, et al. High sensitivity of reverse-hybridization methodology in the detection of KRAS mutations from formalin- fixed paraffin-embedded colorectal cancer samples. Diagn Mol Pathol 2010;19:201-8.
92. Farina Sarasqueta A, Moerland E, de Bruyne H, et al. SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics. J Mol Diagn 2011;13:199-205.
93. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science 1998;281:363-5. (Pubitemid 28340773)
94. Dufort S, Richard MJ, de Fraipont F. Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Anal Biochem 2009;391:166-8.
95. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005;7:413-21. (Pubitemid 41149657)
96. Packham D, Ward RL, Ap Lin V, et al. Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers. Diagn Mol Pathol 2009;18:62-71.
97. Poehlmann A, Kuester D, Meyer F, et al. K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract 2007;203:489-97. (Pubitemid 47065358)
98. Zuo Z, Chen SS, Chandra PK, et al . Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol 2009;22:1023-31.
99. Hadd AG, Houghton J, Choudhary A, et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin- fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn 2013;15:234-47.
100. Peeters M, Oliner KS, Parker A, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 2013;19:1902-12.
101. Tran B, Brown AM, Bedard PL, et al. Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. Int J Cancer 2013;132:1547-55.
102. Webster J, Kauffman TL, Feigelson HS, et al. KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings. Cancer Epidemiol Biomarkers Prev 2013;22:91-101.
103. Lievre A, Artru P, Guiu M, et al. The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011. Eur J Cancer 2013.S0959-8049.
104. Garcia-Alfonso P, Salazar R, Garcia-Foncillas J, et al. Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol 2012;14:726-39.
105. Aubin F, Gill S, Burkes R, et al. Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer. Curr Oncol 2011;18:e180- 4.
106. Jung A, Baretton G, Dietel M, et al. The German quality assurance system for the molecular-pathological detection of KRAS-mutations in colorectal cance. J Clin Oncol 2009;27:15s (suppl; abstr 4018).
107. Deans ZC, Tull J, Beighton G, et al. Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer. Genet Test Mol Biomarkers 2011;15:777-83.
108. Kamel-Reid S, Zhang T, Persons DL, et al. Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma. Arch Pathol Lab Med 2012;136:26-32.
109. van Krieken JH, Normanno N, Blackhall F, et al. Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch 2013;462:27-37.
110. Dijkstra JR, Heideman DA, Meijer GA, et al. KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. Virchows Arch 2013;462:39-46.
111. Dijkstra JR, Opdam FJ, Boonyaratanakornkit J, et al . Implementation of formalinfixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis. J Mol Diagn 2012;14:187-91.
112. Labourier E. Do pre-analytical parameters explain KRAS test sensitivity disparities? J Mol Diagn 2012;14:631-3; author reply 632-3.
113. Farber L, Efrati E, Elkin H, et al. Molecular morphometric analysis shows relative intra-tumoural homogeneity for KRAS mutations in colorectal cancer. Virchows Arch 2011;459:487-93.
114. Goranova TE, Ohue M, Shimoharu Y, et al. Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors. Clin Exp Metastasis 2011;28:427-35.
115. Richman SD, Chambers P, Seymour MT, et al. Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal Cell Pathol (Amst) 2011;34:61-6.
116. Watanabe T, Kobunai T, Yamamoto Y, et al. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum 2011;54:1170-8.
117. Molinari F, Felicioni L, Buscarino M, et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 2011;17:4901-14.
118. Santini D, Galluzzo S, Gaeta L, et al. KRAS molecular analysis? J Clin Oncol 2011;29:e206-7; author reply e208-9.
119. Kimura T, Okamoto K, Miyamoto H, et al. Clinical benefi t of high-sensitivity KRAS mutation testing in metastatic colorectal cancer treated with anti-EGFR antibody therapy. Oncology 2012;82:298-304.
120. Smith G, Bounds R, Wolf H, et al. Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours-implications for personalised cancer medicine. Br J Cancer 2010;102:693-703.
121. Valtorta E, Misale S, Sartore-Bianchi A, et al. KRAS gene ampli fication in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer 2013;133:1259-65.
122. Mekenkamp LJ, Tol J, Dijkstra JR, et al . KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer 2012;12:292.
123. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486:532-6.
124. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12.
125. De Roock W, Claes B, Bernasconi D, et al . Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
126. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS ONE 2009;4:e7287.
127. Parsons BL, Myers MB. Personalized cancer treatment and the myth of KRAS wild-type colon tumors. Discov Med 2013;15:259-67.
128. Bouchahda M, Karaboue A, Saffroy R, et al. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol 2010;66:605-9.
129. Montagut C, Dalmases A, Bellosillo B, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012;18:221-3.
130. Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. Cancer Discov 2013;3:658-73.
131. Custodio A, Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Crit Rev Oncol Hematol 2013;85:45-81.
132. Ruzzo A, Graziano F, Vincenzi B, et al. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist 2012;17:823-9.
133. Mosakhani N, Lahti L, Borze I, et al. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF. Cancer Genet 2012;205:545-51.
134. Pichler M, Winter E, Stotz M, et al. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. Br J Cancer 2012;106:1826-32.